Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis

Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis Deborah K. Armstrong, David Spriggs, Jeremey Levin, Ruth Poulin, Stephen Lane Oncologist 2005; 10: 686-694 Author Information and Disclosures Target Audience: Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the approved indications and treatment schedules for topotecan. Describe the typical pattern of hematologic toxicity during treatment with topotecan. Identify patients who are at higher risk for severe hematologic toxicity during treatment with topotecan. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 25, 2005 Most Recent Review: Oct. 25, 2005* Most Recent Update: Oct. 25, 2005 Date Credit Expires: Oct. 25, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.